DRMA

Dermata Therapeutics, Inc. Common Stock

2.10

USD

DRMA Earnings Reports

Positive Surprise Ratio

DRMA beat 13 of 18 last estimates.

72%

Next Report

Date of Next Report

Mar 17, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$1.57

Implied change from Q3 25 (Revenue/ EPS)

-4.85%

Implied change from Q4 24 (Revenue/ EPS)

-92.38%

Dermata Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 14, 2025, DRMA reported earnings of -1.65 USD per share (EPS) for Q3 25, missing the estimate of -1.62 USD, resulting in a -1.74% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.49% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 3 analysts forecast an EPS of -1.57 USD, with revenue projected to reach -- USD, implying an decrease of -4.85% EPS, and -- of --% in Revenue from the last quarter.

FAQ

What were Dermata Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Dermata Therapeutics, Inc. Common Stock reported EPS of -$1.65, missing estimates by -1.74%, and revenue of $0.00, 0% as expectations.

How did the market react to Dermata Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -7.49%, changed from $3.07 before the earnings release to $2.84 the day after.

When is Dermata Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 17, 2026.

What are the forecasts for Dermata Therapeutics, Inc. Common Stock's next earnings report?

Based on 3 analysts, Dermata Therapeutics, Inc. Common Stock is expected to report EPS of -$1.57 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.